Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias

Experimental and Molecular Pathology

Volumn 79, Issue 1, 2005, Pages 39-41

  Cruse, Julius M ^a   Lewis, Robert E ^a   Pierce, Samuel ^a   Lam, John ^a   Tadros, Yousef ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Aberrant phenotype; Acute myelogenous leukemia; AML; CD56; CD7; CD79a

Indexed keywords

BIOLOGICAL MARKER; CD56 ANTIGEN; CD7 ANTIGEN; CD79A ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL LINEAGE; HEMATOPOIESIS; HUMAN; ONTOGENY; PROGNOSIS;

ANTIGENS, CD; ANTIGENS, CD56; ANTIGENS, CD7; ANTIGENS, CD79; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; PROGNOSIS; RECEPTORS, ANTIGEN, B-CELL; TUMOR MARKERS, BIOLOGICAL;

EID: 22144482284     PISSN: 00144800     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexmp.2005.02.003     Document Type: Article

References (19)

1. D.M. Bahia, M. Yamamoto, M.L. Chauffaille, E.Y. Kimura, J.O. Bordin, M.A. Filgueiras, and J. Kerbauy Aberrant phenotypes I acute myeloid leukemia: a high frequency and its clinical significance Haematologica 86 2001 801 806
2. D. Campana, E. Coustan-Smith, and G. Janossy The immunologic detection of minimal residual disease in acute leukemia Blood 76 1990 163 171
3. E. Coustan-Smith, F.G. Behm, C.A. Hurwitz, G.K. Rivera, and D. Campana N-Cam (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia Leukemia 7 1993 853 858
4. J.M. Cruse, R.E. Lewis, and S. Pierce Aberrant CD7, CD56 and CD79a antigen expression in acute myeloid leukemias FASEB J. 19 2005 A507
5. J. Drach, C. Gattringer, and H. Huber Combined flow cytometric assessment of cell surface antigens and nuclear TdT for the detection of minimal residual disease in acute leukemia Br. J. Haematol. 77 1991 37 42
6. J.L. Frater, N.R. Yaseen, L.C. Peterson, M.S. Tallman, and C.L. Goolsby Biphenotypic acute leukemia with co-expression of CD79a and markers of myeloid lineage Arch. Pathol. Lab. Med. 127 2003 356 359
7. D.R. Head Revised classification of acute myeloid leukemia Leukemia 10 1996 1826 1831
8. A.L. Jackson, and N.L. Warner Preparation, staining, and analysis by flow cytometry of peripheral blood leukocytes N.R. Rose H. Friedman J.L. Fakey Manual of Clinical Laboratory Immunology 3rd ed. 1986 ASM Press Washington, DC 226 235
9. A. Macedo, A. Orfao, M.D. Vidriales, M.C. Lopez-Berges, B. Valverde, M. Conzalez, M.D. Caballero, F. Ramos, M. Martinez, and J. Fernandez-Calvo Characterization of aberrant phenotypes in acute myeloblastic leukemia Ann. Hematol. 70 1995 189 194
10. H.K. Muller-Hermelink, D. Catovsky, E. Montserrat, and N.L. Harris Chronic lymphocytic leukaemia/small lymphocytic lymphoma E.S. Jaffe N.L. Harris H. Stein J.W. Vardiman World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues 2001 IARC Press Lyon
11. D. Raspadori, D. Damiani, M. Michieli, R. Stocchi, S. Gentili, A. Gozzetti, P. Masolini, A. Michelutti, A. Geromin, R. Fanin, and F. Lauria CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome Haematologica 87 2002 1135 1140
12. C.L. Reading, E.H. Estey, Y.O. Huh, D.F. Claxton, G. Sánchez, L.W.M.M. Terstappen, M.C. O'Brien, S. Baron, and A.B. Deisseroth Expression of unusual immunophenotype combinations in acute myelogenous leukemia Blood 81 1993 3083 3090
13. A. Saxena, D.P. Sheridan, R.T. Card, A.M. McPeek, C.C. Mewdell, and L.F. Skinnider Biologic and clinical significance of CD7 expression in acute myeloid leukemia Am. J. Hematol. 58 1998 278 284
14. R. Suzuki, K. Yamamoto, M. Seto, Y. Kagami, M. Ogura, Y. Yatabe, T. Suchi, Y. Kodera, Y. Morishima, T. Takahashi, H. Saito, R. Ueda, and S. Nakamura CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: distinct hematolymphoid disease entity Blood 90 1997 2417 2428
15. R. Suzuki, M. Murata, M. Kami, S. Ohtake, N. Asou, Y. Kodera, M. Tomonaga, Y. Masaki, S. Kusumoto, J. Takeuchi, S. Matsuda, H. Hirai, S. Yorimitsu, N. Hamajima, M. Seto, M. Shimoyama, R. Ohno, Y. Morishima, and S. Nakamura Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0 Int. J. Hematol. 77 2003 482 489
16. L.W.M.M. Terstappen, M. Safford, S. Konemann, M.R. Loken, K. Zurlutter, T. Büchner, W. Hiddemann, and B. Wörmann Flow cytometric characterization of acute myeloid leukemia II. Phenotypic heterogeneity at diagnosis Leukemia 5 1991 757 767
17. N. Tiftik, Z. Bolaman, S. Batun, O. Ayyildiz, A. Isikdogan, G. Kadikoylu, and E. Muftuoglu The importance of CD7 and CD56 antigens in acute leukemias Int. J. Clin. Pract. 58 2004 149 152
18. A. Venditti, G. Del Poeta, F. Buccisano, A. Tamburini, M.C. Cox-Froncillo, G. Aronica, A. Bruno, B. Del Moro, A.M. Epiceno, A. Battaglia, L. Forte, M. Postorino, V. Cordero, S. Santinelli, and S. Amadori Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia Leukemia 12 1998 1056 1063
19. B. Wörman, F. Griesinger, G. Innig, A. Kolkmeyer, S. Toepken, D. Grove, T. Büchner, W. Hiddemann, and W.M. Terstappen Detection of residual leukemic cells in patients with acute myeloid leukemia based on cell surface antigen expression Sangre 37 1992 133 135